Selank has an unusual position among the peptides sold online: it is a registered medicine somewhere. In Russia it is an over-the-counter nasal drop for anxiety, made by the Russian company Peptogen, and it has a published, if small, clinical literature. That makes it look as if its side effects should be well documented. They are not. This page sets out what the Russian label lists, what the trials recorded, what FDA has said, and what the US databases hold. It reports; it does not reassure or warn, and a decision about use or about a symptom belongs with a clinician.
What Selank is and how it compares with the other nootropic peptides is on our cognitive peptides page; the amounts sources state, and why the injected figures trace to no human study, are on our Selank dosage page. How brands appear on this site is on our disclosure page.
The record at a glance
| Source | What it says about side effects | Date |
|---|---|---|
| Russian product description, Selank 0.15% nasal drops | Allergic reactions with individual intolerance; unpleasant taste if drops reach the throat. Contraindicated in pregnancy, breastfeeding, under 18 | Registration 15 July 2025; description dated 22 October 2018 |
| Four patient trials in PubMed | No adverse-event rate for Selank in any abstract | 2008–2020 |
| FDA compounding-risk list | Possible immunogenicity; FDA "lacks important information" on safety in humans | Content current 22 April 2026 |
| openFDA adverse-event database | 0 reports naming selank | Data to 28 October 2026 |
| DailyMed / ClinicalTrials.gov | 0 US labels; 0 registered studies with a Selank arm | 12 November 2026 |
What the Russian label lists
The product description in the Russian drug reference Vidal (Selank 0.15% nasal drops, Vidal) is the closest thing Selank has to a label. Read on 12 November 2026, it gives the registration holder as Peptogen, a Russian research-and-production centre, the current registration as ЛП-№(010951)-(РГ-RU) dated 15 July 2025 with no expiry, and the previous one as ЛСР-003338/09. The product is 1.5 mg of the selank diacetate salt per millilitre with 1 mg of methylparaben as preservative, in a 3 mL dropper bottle, stored at 2–8 °C and sold without prescription.
Its side-effect section is two lines long. In our translation, it says side effects are possible as:
- allergic reactions in people with an individual intolerance;
- an unpleasant taste when the drops pass from the nasal cavity onto the lining of the throat.
The contraindications are pregnancy, breastfeeding, age under 18 and hypersensitivity to the active substance. The description also states that absorption may be lower when the nose is producing more mucus. It claims an absolute bioavailability of 92.8% by the nasal route, with the drug detectable in plasma within 30 seconds and its plasma level falling over 5 to 5.5 minutes; this page found no English-language study reporting those figures, so they stand as the label's own statement. The substance description on the page is dated 22 October 2018, so the side-effect text may predate the 2025 re-registration.
What the trials recorded
A PubMed search on 12 November 2026 returned 137 records for "selank". Combining it with adverse, safety or tolerability returned nine, three of them unrelated to the drug (a turkey-farming survey, a coronary-stent study and a lithium trial matched on other words). The patient studies of Selank itself are these:
| Study | Patients | Comparison | What the abstract says about side effects |
|---|---|---|---|
| Zozulia et al. 2008 (Russian) | 62 with generalised anxiety disorder or neurasthenia | Selank (30) vs medazepam (32) | Nothing. Reports similar anti-anxiety effects and an added "psychostimulant" effect for Selank |
| Medvedev et al. 2014 (Russian) | 60 with anxiety and somatoform disorders | Selank vs phenazepam | States that tolerability was studied; reports no figure |
| Medvedev et al. 2015 (Russian, randomised) | 70 with anxiety, hypochondriac and somatoform disorders | Phenazepam alone (30) vs phenazepam plus Selank (40) | Tolerability measured on the UKU side-effect scale; the combination reduced phenazepam's side effects. No separate Selank figure |
| Panikratova et al. 2020 (English) | 52 healthy volunteers | Selank vs semax vs placebo, single dose, brain imaging | Not reported |
The 2015 trial is the one that measured side effects with a recognised instrument, the UKU scale. What its abstract reports is a finding about the other drug: patients given Selank alongside phenazepam had fewer of phenazepam's own side effects — attention and memory impairment, weakness, sedation, longer sleep, sexual problems, emotional blunting and dizziness on standing — both during treatment and after the tranquilliser was stopped. That is a claim about a combination, from one 70-patient trial, and it does not say how often anything happened on Selank. A 2008 study measured blood cytokines in patients with anxiety disorders after 14 days of Selank (Uchakina et al. 2008), and an earlier laboratory paper described Selank as not causing "side effects typical of most anxiolytics" (Zozulya et al. 2001); neither abstract reports an adverse-event count.
The full texts of the three clinical trials are in Russian and were not read for this page. They may hold tables the abstracts leave out; this page reports only what can be read in English, which is also what FDA's reviewers could read when they set aside untranslated Russian literature in their review of the related peptide semax.
What FDA has said
FDA has never reviewed Selank in full. Selank acetate was nominated for use in US compounding and placed on FDA's list of bulk substances that "may present significant safety risks", then the nomination was withdrawn. The agency's entry, unchanged on the page's 22 April 2026 version (read 12 November 2026 from the Internet Archive's copy of 23 October 2026, because fda.gov did not serve the page to this site's request that night), reads:
"Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."
Immunogenicity means the body forming an immune response to the peptide or to impurities in it. FDA does not say which routes it means. The same list's entry for semax uses almost the same wording; semax then went to FDA's July 2026 advisory committee with a full safety review, and what that review found is on our semax side effects page. Selank did not. What being on that list does and does not mean is explained on our FDA Category 2 list page.
What the US databases hold
- openFDA adverse-event database, searched 12 November 2026 for "selank" in the product name (data updated 28 October 2026): 0 reports. This site's earlier count across fourteen research peptides, on our peptide side effects page, also found none.
- DailyMed, searched the same day: 0 labels. No product containing Selank is approved or listed in the US.
- ClinicalTrials.gov: a search for "selank" returned ten studies, none with Selank as an intervention — the registry's search had matched other words. No study of Selank is registered there.
Products sold online as research chemicals are rarely reported to FDA, so these zeros record an absence of reports and registrations, not an absence of side effects.
What is not established
- How often any side effect occurs. No English-language source gives a rate.
- Injected Selank. The registered product and every trial found used the nose. No human study of Selank by injection was found, so the side effects of the route vendors also sell are unmeasured.
- Long-term use. The clinical trials ran for weeks; none reports follow-up beyond the treatment period apart from the 2015 trial's withdrawal phase.
- Research-market product. The trials used the Russian pharmaceutical product. A vial bought online as "selank" has no registration, and its content, salt form and impurities are whatever its seller's certificate says.
- Interactions. The one combination studied is with the benzodiazepine phenazepam. Interactions with other medicines are not documented.
Who makes the decisions
The Russian label already excludes pregnancy, breastfeeding and anyone under 18. Anyone with an anxiety disorder, anyone taking a benzodiazepine or other sedative, and anyone with allergies has specific reasons to take the question to a clinician. This page reports what the sources state; it does not tell anyone what to use.
Sources and dates
- Vidal drug reference, Selank (Селанк) 0.15% nasal drops: registration holder Peptogen; registration ЛП-№(010951)-(РГ-RU) of 15.07.2025; substance description dated 2018-10-22. Read and translated 12 November 2026.
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of 22 April 2026; read 12 November 2026 via the Internet Archive copy of 23 October 2026.
- Zozulia AA et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18454096. English abstract read 12 November 2026.
- Medvedev et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID 25176261. English abstract read 12 November 2026.
- Medvedev et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID 26356395, doi 10.17116/jnevro20151156133-40. English abstract read 12 November 2026.
- Panikratova et al. Dokl Biol Sci. 2020. PMID 32342318. Abstract read 12 November 2026.
- Uchakina et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18577961. English abstract read 12 November 2026.
- Zozulya et al. Bull Exp Biol Med. 2001. PMID 11550013. Abstract read 12 November 2026.
- PubMed E-utilities: "selank" 137 records; "selank AND (adverse OR safety OR tolerability)" 9 records; 12 November 2026.
- openFDA drug adverse-event endpoint,
patient.drug.medicinalproduct:selank: no matches; data last updated 2026-10-28; queried 12 November 2026. - DailyMed SPL search "selank": 0 results; ClinicalTrials.gov API v2 term "selank": 10 studies, none with a Selank intervention; 12 November 2026.
